Insmed Drug Benefits Patients with Rare, Bacterial Lung Disease, Study Shows

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates—

Insmed drug benefits patients with rare, bacterial lung disease, study shows

Insmed said Monday that the addition of its drug Arikayce to a standard treatment for patients with a rare bacterial lung disease improved respiratory symptoms and increased culture conversion rates.  The study results achieved the goals of a Phase 3 clinical trial designed to show that Arikayce could benefit patients with new occurrences of mycobacterium avium complex (MAC) lung infection who had not yet received antibiotics.  Arikayce was gran…